NCM · Medical - Instruments & Supplies

NXGL (NXGL) Stock

$0.44 -0.57% NCM: NXGL Healthcare

Valuation

MetricValue
Price$0.44
Market Cap$4.03M
P/E Ratio0.72
P/B Ratio1.07
P/S Ratio0.48
EPS (TTM)$0.82
52-Week High$2.89
52-Week Low$0.41
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-52.74%
ROA-19.54%
ROCE-75.00%
Gross Margin-36.36%
Operating Margin-27.27%
Net Margin-28.54%
Debt/Equity1.07
Current Ratio1.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$2.0M$4.0M$9.0M$11.0M
Operating Profit$-3.0M$-3.0M$-3.0M$-4.0M$-3.0M
Net Profit$-4.0M$-5.0M$-3.0M$-3.0M$-3.0M
EPS$-0.77$-0.85$-0.56$-0.50$-0.38
Op Margin-165.7%-163.5%-85.0%-40.9%-29.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$17.0M$10.0M$10.0M$11.0M$10.0M
Total Liabilities$5.0M$3.0M$5.0M$5.0M$6.0M
Cash$13.0M$1.0M$3.0M$2.0M$0
Borrowings$4.0M$2.0M$3.0M$3.0M$3.0M

Latest News

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th GlobeNewswire · Jun 4, 2026 NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration GlobeNewswire · May 19, 2026 Nexgel (NXGL) Q1 2026 Earnings Transcript Motley Fool · May 15, 2026 NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical GlobeNewswire · May 13, 2026 NEXGEL To Report First Quarter 2026 Financial Results on May 15th GlobeNewswire · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-3.0M$-3.0M$-3.0M$-4.0M$-1.0M
Investing Cash Flow$-1.0M$-6.0M$4.0M$-1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$13.0M$-12.0M$2.0M$-1.0M$-1.0M
Free Cash Flow$-3.0M$-3.0M$-4.0M$-4.0M$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio8.41
EV / EBITDA—
FCF Yield-26.16%
Quick Ratio1.02
Interest Coverage—
Return 1Y-81.69%
Return 3Y-79.57%
Return 5Y—

Ownership

Insiders Held14.59%
Institutions Held13.57%
Institutions Float Held15.89%
Institutional HolderSharesReport Date
Geode Capital Management, LLC128,5362026-03-31
Morgan Stanley54,9802026-03-31
Renaissance Technologies, LLC50,9602026-03-31
Vanguard Capital Management LLC48,9202026-03-31
Jane Street Group, LLC42,1382026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ENLV $2.12 -5.36% 0.03 $35.68M 0.00%
FEMY $3.06 -17.52% -0.74 $9.24M 0.00%
GDTC $0.93 -5.99% -4.00 $11.01M 0.00%
HBIO $6.10 +0.16% -0.42 $27.51M 0.00%
IINNInspira Technologies OXY B.H.N. Ltd. $1.26 -5.97% -2.80 $30.34M 0.00%

About NXGL

NXGL is led by CEO Adam R. Levy, employs 19 people, headquartered in US, publicly traded since 2021.

NXGL stock trades at $0.44 with a market capitalization of $4.03M. The stock is valued at a price-to-earnings (P/E) ratio of 0.72, price-to-book of 1.07, price-to-sales of 0.48. Over the past 52 weeks the stock has ranged between $0.41 and $2.89, and currently trades 84.8% below its 52-week high.

On profitability, NXGL generates a return on equity (ROE) of -52.74%, return on capital employed of -75.00%, an operating margin of -27.27%, a net profit margin of -28.54%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides